The August Wellness Index Report, published by Wellness Eternal, shifts the focus from laboratory breakthroughs to the critical work of delivering longevity science to real people. The report, titled "Translational Longevity: From Discovery to Delivery," underscores that the science of living longer is meaningless unless it translates into treatments that patients can access. This discipline, known as translational longevity, is the central theme of the upcoming Translational Longevity Summit in Boston, hosted by Boston BioLife and the Healthspan Action Coalition.
The report identifies three key signals driving the field forward. First, cell science is moving from proof of concept to real clinical delivery. Decades of research in transplantation and cell therapy are now being integrated into mainstream longevity practices, with an emphasis on reversing, rather than merely managing, the drivers of disease and aging. Second, evidence is emerging as the critical bridge between research and practice. As longevity claims proliferate, the ability to distinguish proven therapies from promising but unverified ones becomes increasingly valuable for clinicians, executives, and policymakers. Third, clinical strategy and systems are proving essential to scaling care. Even the most effective therapy will fail if healthcare systems cannot deliver it safely and consistently, highlighting the need for operational rigor and smarter care models.
The August edition features three experts who epitomize these signals. Dr. Camillo Ricordi, a professor at the University of Miami, anchors the first signal with his work in translational cell therapy. Dr. David Barzilai, a Harvard Medical School lecturer and longevity medicine physician, represents the second signal, focusing on evidence-based and precision medicine. He has served as medical editor of Harvard Health Publishing's Pathways to Longevity and is known for making complex science accessible to diverse audiences. Dr. Suzie Robertson, a clinical pharmacist and healthcare strategist at Matrix Biologics, embodies the third signal, with nearly two decades of experience improving patient safety and care delivery models.
The Translational Longevity Summit, scheduled for October 7-11 at the Harvard Enterprise Research Campus in Boston, will bring these voices together. Joseph Krieger, President and Founder of Boston BioLife, and Bernard Siegel, founder of the Healthspan Action Coalition, will host the event. Krieger has spent over 25 years in healthcare and life sciences, working to streamline translational medicine through accredited education and collaboration. Siegel, a patient advocate and attorney, has been instrumental in the stem cell and regenerative medicine advocacy movement, having co-chaired twenty World Stem Cell Summits.
The Wellness Index Report applies a rigorous four-step verification process, including expert nomination, customer feedback, clinical review, and ongoing performance tracking. This methodology ensures that only solutions meeting its integrity-first standard receive visibility. The full August report is available at wellnessindexreport.com.
Lindsay O'Neill-O'Keefe, Founder of Wellness Eternal and creator of the Wellness Index Report, emphasizes that "the future of longevity is translational. The breakthroughs are real, but they only matter when they reach people." She adds, "Discovery is only half the job. Delivery is the rest." The summit and the report both aim to accelerate the integration of longevity science into everyday medical practice, ensuring that the promise of extended healthspan becomes a reality for all.
